Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

Recursion Pharmaceuticals (RXRX) has been drawing investor attention after recent trading shifts, with the stock closing at US$3.01 and showing mixed performance over the past week, month, and past ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predi ...

UIUC and Stanford's RecursiveMAS lets AI agents collaborate in embedding space instead of text, cutting token usage by 75% ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding.

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals (RXRX) has been in focus after fresh clinical updates on REC-4881 and REC-1245, along with ongoing FDA discussions for a potential registrational pathway, drew attention away ...

Three humans, eight AI team members, one product. The multi-agent collaboration pattern Stark Insider readers have been ...

Recursion Pharmaceuticals reported Q1 2026 progress on its AI-driven drug discovery programs, highlighting its first clinical proof of concept and multiple upcoming trial readouts. The company has ...

What happens to language when a growing amount of text published in the press, online and on social media is written by ...